Experimental CAR-T therapy GI001 takes aim at tough lymphoma

NCT ID NCT07584850

Not yet recruiting Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new CAR-T cell therapy called GI001 in 9 adults with relapsed or refractory B-cell lymphoma. Participants receive a single infusion of engineered immune cells designed to attack cancer. The main goals are to check safety and find the right dose, with preliminary effectiveness also measured.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GI001 (a CAR-T cell therapy targeting CD19)
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat B-cell lymphoma.
What could go wrong: This is a very early, small trial (9 people) focused on safety. It may not show strong benefit, and there are known risks like cytokine release syndrome and nerve-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL NON HODGKIN LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.